R&D and Health Cooperation Protocol Between BMS Turkey and TÜSEB
An official protocol was signed between Bristol Myers Squibb Turkey and TÜSEB to increase Turkey's R&D capacity in the field of health sciences and technologies.
Bristol Myers Squibb (BMS) Turkey and the Presidency of Turkey Health Institutes (TÜSEB) have signed a comprehensive cooperation protocol to strengthen R&D capacity in the fields of health sciences and technologies.
Scope of the Protocol and Signing Process
Bristol Myers Squibb Turkey and the Presidency of Turkey Health Institutes came together to support the country's R&D capacity in the field of health sciences and technologies.
Brought to life with the signatures of TÜSEB President Prof. Dr. Ümit Kervan and BMS Turkey General Manager Ece Kaşıkcı, the protocol aims to develop joint studies in various branches of health technologies.
Focused Health Technology Areas
The protocol includes critical topics such as cancer, clinical research, biomedical technologies, biotechnology, pharmaceuticals and drug delivery systems, and medical devices.
In addition, artificial intelligence, biomaterials, medical imaging systems, and diagnostic kits are among the focus points of the study.
Joint Studies and Infrastructure Models
Within this framework, it is planned to implement joint R&D and product development studies, and to develop scientific research and project supports.
It is also aimed to create new models for the joint use of research centers, laboratories, technological infrastructures, and clinical areas.
Executive Evaluations and Vision
BMS Turkey General Manager Ece Kaşıkcı stated that they work with the goal of turning the power of science into meaningful results for patients and found this cooperation very valuable.
Kaşıkcı conveyed that the protocol will create long-term values that support the transformation of scientific capacity in Turkey into innovative solutions and strengthen the research ecosystem.